Immunological and inflammatory profiles in mild and severe cases of COVID-19

Vista sencilla de ítem
dc.creatorSong, Jin-Wen
dc.creatorZhang, Chao
dc.creatorFan, Xing
dc.creatorMeng, Fan-Ping
dc.creatorXu, Zhe
dc.creatorXia, Peng
dc.creatorCao, Wen-Jing
dc.creatorYang, Tao
dc.creatorDai, Xiao-Peng
dc.creatorWang, Si-Yu
dc.creatorXu, Ruo-Nan
dc.creatorJiang, Tian-Jun
dc.creatorLi, Wen-Gang
dc.creatorZhang, Da-Wei
dc.creatorZhao, Peng
dc.creatorShi, Ming
dc.creatorAgrati, Chiara
dc.creatorIppolito, Giuseppe
dc.creatorMaeurer, Markus
dc.creatorZumla, Alimuddin
dc.creatorWang, Fu-Sheng
dc.creatorZhang, Ji-Yuan
dc.date.accessioned2020-07-22T20:52:18Z
dc.date.available2020-07-22T20:52:18Z
dc.date.created2020-07-08
dc.description.abstractenglishCOVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical, and management outcome features of COVID-19 patients have been defined rapidly, the inflammatory and immune profiles require definition as they influence pathogenesis and clinical expression of COVID-19. Here we show lymphopenia, selective loss of CD4+ T cells, CD8+ T cells and NK cells, excessive T-cell activation and high expression of T-cell inhibitory molecules are more prominent in severe cases than in those with mild disease. CD8+ T cells in patients with severe disease express high levels of cytotoxic molecules. Histochemical studies of lung tissue from one fatality show sub-anatomical distributions of SARS-CoV-2 RNA and massive infiltration of T cells and macrophages. Thus, aberrant activation and dysregulation of CD8+ T cells occur in patients with severe COVID-19 disease, an effect that might be for pathogenesis of SARS-CoV-2 infection and indicate that immune-based targets for therapeutic interventions constitute a promising treatment for severe COVID-19 patients.spa
dc.format.extent10 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41467-020-17240-2spa
dc.identifier.issn2041-1723spa
dc.identifier.otherhttps://www.nature.com/articles/s41467-020-17240-2#article-infospa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10988
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectPerfiles inmunológicosspa
dc.subjectPerfiles inflamatoriosspa
dc.subject.keywordImmunological profilesspa
dc.subject.keywordInflammatory profilesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleImmunological and inflammatory profiles in mild and severe cases of COVID-19spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41467-020-17240-2.pdf
Tamaño:
2.99 MB
Formato:
Adobe Portable Document Format
Descripción:
Ver documento
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS